Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LIfT BioSciences has demonstrated strong preclinical data showing that its Immunomodulatory Alpha Neutrophils ("IMANs") can both directly kill cancer cells and modulate the tumor microenvironment to recruit the patient’s own immune system. The platform aims to overcome resistance mechanisms in solid tumors by replacing pro-tumor neutrophils with anti-tumor IMANs. The first-in-human clinical trials are expected imminently following a successful £10 million Series A raise in September 2024[5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lift Care.